Indivior Pharmaceuticals annual ebitda margin
2021
2022
2023
2024
2025
Indivior Pharmaceuticals EBITDA Margin Growth & History (INDV)
Indivior Pharmaceuticals's ebitda margin was 21.95% for fiscal 2025.
View full Indivior Pharmaceuticals company overviewIndivior Pharmaceuticals annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 21.95% | +17.41 pp |
| 2024 | 2024-12-31 | 4.55% | +17.08 pp |
| 2023 | 2023-12-31 | −12.53% | −5.32 pp |
| 2022 | 2022-12-31 | −7.21% | −36.04 pp |
| 2021 | 2021-12-31 | 28.82% | — |
Indivior Pharmaceuticals quarterly ebitda margin
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 47.23% | +22.73 pp |
| Q1 2026 | 2026-03-31 | 43.85% | +17.91 pp |
| Q4 2025 | 2025-12-31 | 23.25% | +6.14 pp |
| Q3 2025 | 2025-09-30 | 14.65% | +1.95 pp |
| Q2 2025 | 2025-06-30 | 24.50% | +63.30 pp |
| Q1 2025 | 2025-03-31 | 25.94% | −2.23 pp |
| Q4 2024 | 2024-12-31 | 17.11% | — |
| Q3 2024 | 2024-09-30 | 12.70% | — |
| Q2 2024 | 2024-06-30 | −38.80% | — |
| Q1 2024 | 2024-03-31 | 28.17% | — |
Indivior Pharmaceuticals ebitda margin trends
Between the periods ended 2021-12-31 and 2025-12-31, Indivior Pharmaceuticals's ebitda margin decreased from 28.82% to 21.95%, a change of −6.87 percentage points. The latest reported quarter, Q2 2026, shows 47.23%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Indivior Pharmaceuticals source filings ↗